Extemporaneous drug formulations

doi:10.1016/j.clinthera.2008.11.020

Clinical Therapeutics

Volume 30, Issue 11, November 2008, Pages 2112-2119

https://doi.org/10.1016/j.clinthera.2008.11.020 Get rights and content

Abstract

Background: Access to a special dosage form of a medication is essential when administration to infants and children and selected other populations is required. Some drugs necessary for pediatric patients are not commercially available in dosage forms appropriate for use in this population. These drugs may be prepared extemporaneously for use in individual patients. Physical and chemical properties of drugs and excipients should be considered when preparing extemporaneous formulations. These formulations, however, may lack studies to document stability, bioavailability, pharmacokinetics, pharmacodynamics, efficacy, and tolerability.

Objective: The goal of this article was to discuss factors involved in extemporaneous compounding of pediatric dosage forms.

Methods: The proceedings from a Pediatric Formulation Initiative workshop sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, held December 6 and 7, 2005, in Bethesda, Maryland, were used as a source of information for this article. A literature search of PubMed/ MEDLINE (1966-October 2008) was also conducted, using the search terms extemporaneous, drug formulations, and pediatric.

Results: Access to age-appropriate drug formulations is critical to provide effective and well-tolerated medications to patients. There continues to be a need for extemporaneous formulations of brand and generic drugs for neonates, infants, and children. Potential solutions to current limitations include the need to develop a prioritized list of essential formulations, increased funding of research, dissemination of data, and monitoring of clinical effectiveness and tolerability during use in various age groups of pediatric patients and the sharing of these clinical experiences.

Conclusion: To achieve desired therapeutic outcomes in pediatric patients, access to age-appropriate, stable, effective, and well-tolerated drug formulations is essential.

References (10)

MC Nahata et al.
Pediatrics
JL Blumer
Off-label uses of drugs in children
Pediatrics
(1999)
V Pai et al.
Need for extemporaneous formulations in pediatric patients
J Pediatr Pharmacol Ther
(2001)
MC Nahata et al.
A Ghulam et al.
Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids
Ann Pharmacother
(2007)

There are more references available in the full text version of this article.

Cited by (112)

Development of an extemporaneous preparation formulation using a simple and non-solubilizing matrix for first in human clinical study
2024, International Journal of Pharmaceutics
Extemporaneous preparation (EP) formulation is an attractive strategy to accelerate the formulation development of new chemical entities for first entry into human study. In this work, an EP suspension formulation for a development drug candidate GDC-6599 was successfully developed. The formulation spanned a wide concentration range from 0.1 to 2.0 mg/mL. A non-solubilizing vehicle, 0.6 % (w/v) methylcellulose solution was used to suspend GDC-6599. An aversive agent denatonium benzoate at an extremely low level (6 ppm) was applied as a taste masking agent. This enabled a simple matrix for the analysis of related substances from GDC-6599 during all stability studies. Microcrystalline cellulose at 10 mg/mL concentration was added to the EP formulation to generate a suspension appearance, leading to the success of using a single placebo for matching active formulation at all concentrations. The developed formulation demonstrated excellent homogeneity, sufficient stability and passed microbiological enumeration test. Rinsing performance test demonstrated that greater than 99.8 % amount of drug was successfully recovered by rinsing with water twice, providing guidance for clinical dosing. Biopharmaceutical assessment was conducted by both in silico simulation and in vitro tests. Greater than 90 % bioaccessibility of the EP suspension formulation was obtained via an in vitro system mimicking the human gastrointestinal absorption, consistent with the result from the in silico modeling. The developed EP formulation was successfully used to support the early single ascending dose (SAD) cohorts of GDC-6599 Phase I clinical study. The formulation matrix and assessment workflow developed in this work are generalizable as a platform for EP formulation development of new chemical entities for early phase clinical studies.
Development of ivermectin orally disintegrating tablets using factorial design: In-vitro evaluation and in vivo absorption pattern in rats
2023, Journal of Drug Delivery Science and Technology
The objective of the present study was to develop orally disintegrating tablets (ODTs) containing ivermectin (IVM) using a Design of Experiments (DoE) approach. The ODTs were composed of a diluent, superdisintegrant, lubricant, glidant, and sweetening agent, and were produced through direct compression. The formulations (F1–F8) were assessed by DoE, and the most appropriate ones were developed as porous tablets (direct compression followed by sublimation), with previous incorporation of ammonium bicarbonate as sublimating agent (F9–F10). This study identified that the combination of mannitol and croscarmellose provides ODTs with appropriate critical quality attributes. Pre-compression analyses did not show any drug-excipient incompatibility. F9 was found to have the most favourable quality properties with a disintegration time of 16.9 s, hardness of 2.8 Kp, and proper friability. In vitro dissolution profiles indicated that porous ODTs exhibited better drug dissolution performance than non-porous ones. Additionally, F9 presented an excellent stability behaviour, and the preliminary in vivo assessment revealed that IVM was rapidly absorbed and recovered in the bloodstream for at least 25 h post-treatment in rats. In conclusion, the results of the study demonstrate successful development and characterization of IVM ODTs, which could potentially improve adherence to paediatric treatment and address orphan formulation requirements.
What Are Special Considerations for Dosing Medications in Pediatric Populations?
2023, Evidence-Based Practice of Palliative Medicine, Second Edition
This chapter provides an overview of the special considerations for dosing medications in pediatric populations receiving palliative care with attentiveness to pharmacokinetics and pharmacodynamics. Four dosing methods are reviewed. A summary of convenient and safe dosing routes in children is provided with attentiveness to supportive care during terminal physiological changes. The chapter includes an overview of the unique pharmaceutical needs of the neonatal population and safe dosing cautions in the setting of childhood obesity.
Pediatric clinical pharmacology and therapeutics
2021, Atkinson's Principles of Clinical Pharmacology
Along the developmental and growth spectrum from infancy to adulthood, dynamic changes occur in organ size and function, body composition, protein expression, cellular function, and basic physiology. These changes throughout development impact drug absorption, distribution, metabolism, and excretion. Developmental differences are also observed to impact pharmacodynamic response. As children are not just adults with a smaller stature and certainly are not so from a biological or physiologic perspective, the influence of developmental changes within the body must be considered regarding drug handling and drug effect. This chapter provides foundational knowledge to understand the unique aspects of clinical pharmacologic principles important to the development and use of drugs in the pediatric age group.
Cost-effectiveness and pricing of caffeine
2020, Seminars in Fetal and Neonatal Medicine
In a formal economic evaluation ancillary to the Caffeine for Apnea of Prematurity trial, caffeine was shown to reduce costs while simultaneously improving clinical outcomes. Although these results still apply, the current price of caffeine is substantially higher than when it was introduced. Such pharmaceutical price growth contributes appreciably to medical costs and inflation. In this review, the examples of caffeine and surfactant show how prices are determined for the neonatology formulary. Drivers include small market size, government-imposed barriers to competition designed to encourage innovation, high willingness-to-pay, failure of government buyers to exercise their market power, and asymmetries in knowledge about costs and effects between producers and patients. Many of these factors are exercised at the national policy or market levels. However, by conducting rigorous clinical trials and economic evaluations, neonatologists can still ensure that the drugs they prescribe are both efficacious and represent good use of societal resources.
3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations
2024, Nutrients

View all citing articles on Scopus

View full text

Extemporaneous drug formulations

Abstract

Pediatrics

Off-label uses of drugs in children

Pediatrics

Need for extemporaneous formulations in pediatric patients

J Pediatr Pharmacol Ther

Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids

Ann Pharmacother